Lithium carbonate
لیتیوم
🧠 Nervous SystemMood stabilizer
Market / country: 🇺🇸 USA
Lithobid (US)
🧮 Dose calculator
Bipolar I disorder — manic or mixed episode · Regimen source: FDA Lithium · 2.2, Table 1
- • Acute goal: 600 mg 2–3 times daily (0.8–1.2 mEq/L); maintenance 300–600 mg 2–3 times daily (0.8–1.0). Check serum level after 3 days, 12 h post-dose. FDA Lithium · 2.2, Table 1FDA Lithium · 2.2
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Not established under 7 years. FDA Lithium · 8.4
- ⛔ Hypersensitivity to any inactive ingredient. FDA Lithium · 4
Warnings
- • Boxed warning: lithium toxicity can occur close to therapeutic levels; serum level testing must be available before starting. FDA Lithium · WARNING: LITHIUM TOXICITY
Monitoring
- • Before start: renal function, vitals, electrolytes, thyroid, pregnancy. Check serum level after any dose change or new interacting drug (diuretics, NSAIDs, RAS antagonists, metronidazole). FDA Lithium · 2.1FDA Lithium · 2.3
Formulations
- 300 mg tablet (scored) — tablet 🇺🇸 USA FDA Lithium · 3
- 150 mg capsule — capsule 🇺🇸 USA FDA Lithium · 3
- 300 mg capsule — capsule 🇺🇸 USA FDA Lithium · 3
👥 Special populations
- 🤰 PregnancyDangerous / avoid
Label: can cause fetal harm. Dangerous in pregnancy. FDA Lithium · 8.1
“Risk Summary: Lithium may cause harm when administered to a pregnant woman.”
- 🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Lithium · 8.2
“Breastfeeding is not recommended with maternal lithium use; however, if a woman chooses to breastfeed, the infant should be closely monitored for signs of lithium toxicity.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Lithium · 8.4
“The safety and effectiveness of lithium for monotherapy treatment of acute manic or mixed episodes of bipolar I disorder and maintenance monotherapy of bipolar I disorder in pediatric patients ages 7 to 17 years of age have been established in an acute-phase clinical trial of 8 weeks in duration followed by a 28-week …”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Lithium · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other treatment.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA018558
- DailyMed (FDA label)FDA Lithium
- MedlinePlus (NIH)Lithium
- WHO ATC/DDDN05AN01
- Darooyab (Iran)Lithium-Carbonate
🇮🇷 Registered in Iran Darooyab · G-591/Lithium-Carbonate
Dosage forms with Iranian generic codes, per Darooyab.
- 09674 · LITHIUM 295MG TAB · قرص لیتیوم ۲۹۵ میلیگرم
- 12578 · LITHIUM CARBONATE 200MG TAB · قرص لیتیوم کربنات ۲۰۰ میلیگرم
- 00767 · LITHIUM CARBONATE 300MG TAB · قرص لیتیوم کربنات ۳۰۰ میلیگرم
- 00768 · LITHIUM CARBONATE SR 400MG TAB · قرص آهستهرهش لیتیوم کربنات ۴۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Lithium · 3FDA Lithium · 2.2, Table 1FDA Lithium · 2.2FDA Lithium · 8.4FDA Lithium · 4FDA Lithium · WARNING: LITHIUM TOXICITYFDA Lithium · 2.1FDA Lithium · 2.3FDA Lithium · 8.1FDA Lithium · 8.2FDA Lithium · 8.5FDA Lithium · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-591/Lithium-Carbonate
- Clinical review⚠ Unverified